“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in CHF
Last close As at 30/03/2023
CHF50.00
▲ −0.10 (−0.20%)
Market capitalisation
CHF2,920m
BB Biotech, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech Index (in CHF) but managed on a bottom-up basis, with a focused c 20–35 stock portfolio.
Investment Companies
Investment Companies
Investment Companies
Investment Companies
Analyst, Investment Trusts
Claude Mikkelsen
Director of IR
Daniel Koller
Head of investment management
Dr Silvia Siegfried-Schanz
Director of IR
Erich Hunziker
Chairman
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (7.9) | (9.6) | (21.6) |
| Relative | (5.7) | (9.8) | (12.0) |
| 52 week high/low | CHF67.7/CHF50.0 |
According to BB Biotech’s (BION’s) investment team, the biotech industry remains in a very good position. Following a sell-off in the last two years, valuations are still close to the levels seen three years ago, reflecting ongoing challenges and despite the fundamental industry strength. In the sector, BION is differentiated from the Nasdaq Biotechnology Index by its concentrated portfolio (c 30 stocks). The investment team anticipates that 2023 will include multiple catalysts for the sector and for BION portfolio companies, including product launches, important clinical trial results, licensing deals and renewed M&A activity. During 2022 the investment manager, Bellevue Asset Management, strengthened the investment team with three new members (two data scientists and one neurologist).
